Dianthus Therapeutics DNTH Operating lease right-of-use asset amortization
Operating lease right-of-use asset amortization at other companies
Other financials
Where this comes from
Reported directly by Dianthus Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense.
The official record: Dianthus Therapeutics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Dianthus Therapeutics's operating lease right-of-use asset amortization.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Dianthus Therapeutics's operating lease right-of-use asset amortization?
- Dianthus Therapeutics (DNTH) reported operating lease right-of-use asset amortization of $44K in Q1 2026.
- How has Dianthus Therapeutics's operating lease right-of-use asset amortization changed year-over-year?
- Dianthus Therapeutics's operating lease right-of-use asset amortization decreased by 58.5% year-over-year, from $106K to $44K.